Home
HelpTest Code NGCLN MayoComplete Chronic Lymphoid Neoplasms, Next-Generation Sequencing, Varies
Shipping Instructions
Whole blood, bone marrow aspirate, and body fluid specimens must arrive within 14 days of collection.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Bone marrow aspirate
Container/Tube:
Preferred: Lavender or pink top EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Specimen Stability Information: Ambient (preferred) 14 days/Refrigerate
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender or pink top (EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix peripheral blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as peripheral blood.
Specimen Stability Information: Ambient (preferred) 14 days/Refrigerate
Specimen Type: Paraffin-embedded tissue
Container/ Tube: Paraffin block
Collection Instructions:
1. Send 1 representative slide stained with hematoxylin and eosin
2. Minimum amount of tumor nuclei is 20%
3. Required amount of tissue area is at least 25 mm(2)
4. Tissue should be fixed in 10% neutral-buffered formalin. Other fixatives are not acceptable.
5. Decalcified specimens (eg, bone marrow core biopsies) are not acceptable.
Specimen Stability Information: Ambient
Specimen Type: Tissue slide
Slides: 10 unstained slides
Container/ Tube: Transport in plastic slide holders.
Collection Instructions:
1. Send 10 unstained, nonbaked slides with 5-micron thick sections of tissue and 1 representative slide stained with hematoxylin and eosin.
2. Minimum amount of tumor nuclei is 20%
3. Required amount of tissue area is at least 25 mm(2)
4. Tissue should be fixed in 10% neutral-buffered formalin. Other fixatives are not acceptable.
5. Decalcified specimens (eg, bone marrow core biopsies) are not acceptable.
Specimen Stability Information: Ambient
Specimen Type: Frozen tissue
Container/Tube: Plastic container
Specimen Volume: 100 mg
Collection Instructions: Freeze tissue within 1 hour of collection
Specimen Stability Information: Frozen
Specimen Type: Body fluid
Container/Tube: Sterile container
Specimen Volume: 5 mL
Specimen Stability Information: Refrigerated 14 days/Frozen
Specimen Type: Extracted DNA
Container/Tube: 1.5- to 2-mL tube
Specimen Volume: Entire specimen
Collection Instructions:
1. Label specimen as extracted DNA and source of specimen.
2. Indicate volume and concentration of DNA on label.
Specimen Stability Information: Frozen (preferred)/Refrigerated/Ambient
Forms
Secondary ID
618476Useful For
Aiding in establishing diagnosis, refining prognosis, and potentially identifying targeted therapies for the optimal management of patients with chronic or low-grade B-cell lymphoid neoplasms
Highlights
This test utilizes next-generation sequencing for the detection of somatic mutations with diagnostic, prognostic, or therapeutic value in a set of genes associated with chronic or clinically "low grade" lymphoid neoplasms.
Special Instructions
Method Name
Next-Generation Sequencing (NGS)
Reporting Name
Chronic Lymphoid Neoplasms, NGS, VSpecimen Type
VariesSpecimen Minimum Volume
Whole blood, bone marrow aspirate, body fluid: 1 mL; Frozen tissue: 50 mg; Extracted DNA: 100 microliters (mcL) at 20 ng/mcL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Specimens that have been decalcified (all methods) Bone marrow core biopsies Paraffin shavings Fixatives other than 10% neutral-buffered formalin for paraffin-embedded tissue Moderately to severely clotted bone marrow aspirate |
Reject |
Clinical Information
This test is intended to evaluate a targeted set of genes involved in a heterogeneous group of chronic lymphoid neoplasms that includes chronic lymphocytic leukemia (CLL) and various low-grade B-cell lymphomas. The test includes actionable targets to aid in the differential diagnosis of low-grade B-cell lymphomas (eg, hairy cell leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma), predict prognosis (eg, risk stratification in CLL), and evaluate therapeutic options or efficacy (eg, ibrutinib therapy in CLL, EZH2 [enhancer of zeste homolog 2] inhibitors in follicular lymphoma). Genomic analysis by next-generation sequencing is complementary to the standard evaluation in the classification and management of patients with chronic lymphoid neoplasms.
Reference Values
An interpretive report will be provided.
Interpretation
Genomic variants detected by this test will be documented in a detailed laboratory-issued report. This report will contain information regarding the detected alterations and their associations with prognosis or possible therapeutic implications in chronic lymphoid neoplasms. The information in the clinical report may be used by the patient’s clinician to help guide decisions concerning management. Final interpretation of next-generation sequencing results requires correlation with all relevant clinical, pathologic, and laboratory findings and is the responsibility of the managing clinician.
Cautions
This test is a targeted next-generation sequencing (NGS) panel assay that encompasses 25 genes with variable full exon, partial region (including select intronic or noncoding regions), or hot spot coverage (depending on specific genetic locus). Therefore, this test will not detect other genetic abnormalities in genes or regions outside the specified target areas. The test detects single-base substitutions (ie, point mutations), as well as small insertion or deletion type events. This test is not configured to detect structural genomic rearrangements (ie, translocations), gene fusions, copy number alterations, or large-scale (segmental chromosome region) deletions and other complex genomic changes.
This assay does not distinguish between somatic and germline alterations in analyzed gene regions, particularly with variant allele frequencies near approximately 50% or 100%. If nucleotide alterations in genes associated with germline mutation syndromes are present and there is a strong clinical suspicion or family history of malignant disease predisposition, additional genetic testing and appropriate counseling may be indicated. Some apparent mutations classified as variants of undetermined significance may represent rare or low population frequency polymorphisms.
Prior treatment for hematologic malignancy could affect the results obtained in this assay. Particularly, a prior allogeneic hematopoietic stem cell transplant may cause difficulties in either resolving somatic or polymorphic alterations or assigning variant calls correctly to donor and recipient fractions, if pertinent clinical or laboratory information (eg, chimerism engraftment status) is not provided.
Inadequate samples (eg, insufficient DNA quantity or quality) will preclude further testing and will be noted in the interpretive report. For formalin-fixed, paraffin-embedded specimens, NGS testing should not be pursued if the quality of the biopsy specimen is poor (eg, limited sample size, presence of extensive necrosis or fibrosis), or the target tumor cell population is low (<20%).
Clinical Reference
1. Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2017. WHO Classification of Tumours, Vol 2
2. Onaindia A, Medeiros LJ, Patel KP. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol. 2017;30(10):1338-1366. doi:10.1038/modpathol.2017.58
3. Jajosky AA, Havens NP, Sadri N, et al. Clinical utility of targeted next-generation sequencing in the evaluation of low-grade lymphoproliferative disorders. Am J Clin Pathol. 2021;156(3):433-444
4. Davis AR, Stone SL, Oran AR, et al. Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. Mod Pathol. 2021;34(5):904-921
5. Stewart JP, Gazdova J, Darzentas N, et al. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Adv. 2021;5(16):3188-3198
6. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791-2796. doi:10.1182/blood-2014-01-550905
7. Morin RD, Arthur SE, Assouline S. Treating lymphoma is now a bit EZ-er. Blood Adv. 2021;5(8):2256-2263
8. Thangavadivel S, Byrd JC. Gly101Val BCL2 Mutation: One step closer to understanding Venetoclax resistance in CLL. Cancer Discov. 2019;9(3):320-322. doi:10.1158/2159-8290.CD-19-0029
9. Lee J, Wang YL. Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia. J Mol Diagn. 2020;22(9):1114-1125
10. Liebers N, Roider T, Bohn JP, et al. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia. 2020;34(5):1454-1457
Method Description
This is a target-enriched next-generation sequencing (NGS) panel. DNA is extracted from validated specimen sources including, but not limited to, peripheral blood, bone marrow aspirate, and formalin-fixed paraffin embedded tissues. Library preparation for NGS is performed followed by probe hybridization and capture. Sequencing of the final sample library is performed on a NGS instrument. Following bioinformatic processing of the sequencing data, the sequencing results are interpreted to provide a final clinical report. Genomic alterations are called according to human genome reference build GRCh37 (hg19).(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
Report Available
16 to 21 daysSpecimen Retention Time
Bone marrow aspirate/whole blood: 2 weeks; DNA: 3 months; Tissue: 1 month; FFPE tissue: Unused portions of blocks will be returned to the client. Unstained slides/body fluid: Not retainedPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81450
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| NGCLN | Chronic Lymphoid Neoplasms, NGS, V | 104238-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| MP065 | Specimen Type | 31208-2 |
| MP066 | Indication for Test | 42349-1 |
| 618485 | NGCLN Result | No LOINC Needed |
| 618486 | Pathogenic Mutations Detected | 82939-0 |
| 618487 | Interpretation | 69047-9 |
| 618489 | Variants of Unknown Significance | 93367-1 |
| 618490 | Additional Information | 48767-8 |
| 618488 | Clinical Trials | 82786-5 |
| 618491 | Method Summary | 85069-3 |
| 618492 | Disclaimer | 62364-5 |
| 618493 | Panel Gene List | 36908-2 |
| 618494 | Reviewed By | 18771-6 |